Nurix Therapeutics Inc Forecast, price target & analysts
Nurix Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Nurix Therapeutics Inc Classifications & Recommendation:
Nurix Therapeutics Inc Price Target
| Target Price | $32.28 |
| Price | $15.00 |
| Potential |
115.19%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Nurix Therapeutics Inc 2026 .
The average Nurix Therapeutics Inc target price is $32.28.
This is
115.19%
register free of charge
$41.00
173.33%
register free of charge
$17.00
13.33%
register free of charge
|
|
| A rating was issued by 18 analysts: 17 Analysts recommend Nurix Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Nurix Therapeutics Inc stock has an average upside potential 2026 of
115.19%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Nov '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 54.55 | 59.01 |
| 29.15% | 8.18% | |
| EBITDA Margin | -360.40% | -405.95% |
| 96.22% | 12.64% | |
| Net Margin | -400.56% | -418.45% |
| 53.39% | 4.47% |
16 Analysts have issued a sales forecast Nurix Therapeutics Inc 2025 . The average Nurix Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Nurix Therapeutics Inc EBITDA forecast 2025. The average Nurix Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Nurix Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Nurix Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Nov '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.88 | -3.25 |
| 8.68% | 12.85% | |
| P/E | negative | |
| EV/Sales | 9.44 |
8 Analysts have issued a Nurix Therapeutics Inc forecast for earnings per share. The average Nurix Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Nurix Therapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Nurix Therapeutics Inc...
Current Nurix Therapeutics Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley | Locked ➜ Locked | Locked | Feb 03 2025 |
| RBC Capital | Locked ➜ Locked | Locked | Jan 29 2025 |
| Stifel | Locked ➜ Locked | Locked | Jan 29 2025 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 29 2025 |
| Needham | Locked ➜ Locked | Locked | Jan 29 2025 |
| JP Morgan | Locked ➜ Locked | Locked | Jan 29 2025 |
| Stephens & Co. | Locked ➜ Locked | Locked | Jan 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Morgan Stanley: Locked ➜ Locked
|
Feb 03 2025 |
|
Locked
RBC Capital: Locked ➜ Locked
|
Jan 29 2025 |
|
Locked
Stifel: Locked ➜ Locked
|
Jan 29 2025 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 29 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Jan 29 2025 |
|
Locked
JP Morgan: Locked ➜ Locked
|
Jan 29 2025 |
|
Locked
Stephens & Co.: Locked ➜ Locked
|
Jan 21 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
